Stability, microbiology and preservative testing: what each cosmetic report can tell you

Three questions that should not share one checkbox

A brand might receive three attachments labeled “testing” and assume they collectively complete a product file. A more useful first step is to ask what each attachment actually investigates. Our suggested division is change over time, microbial quality of the examined sample, and the performance of antimicrobial protection. The overlap matters, but so do the boundaries.

This article focuses on how a brand team can organize and question laboratory evidence. It does not prescribe a test program or laboratory acceptance criteria. Product composition, intended use, packaging, market and the reviewer’s assessment determine the appropriate work. Discuss the scientific plan with a suitably qualified laboratory or reviewer before treating a familiar test name as a requirement.

Stability: what changed under the study conditions?

ISO/TR 18811:2018 provides a framework for cosmetic stability assessment. Its published scope explicitly does not set universal test conditions, parameters or criteria; the manufacturer must specify and justify the protocol. A familiar accelerated-study duration is therefore not a universal ISO requirement. ISO’s stability guidance scope.

When organizing a stability report, capture the composition tested, package used, conditions, timepoints, attributes measured and stated findings. Identify whether the document is an interim update or a completed report. These are practical review questions, not a replacement protocol. They help the reviewer locate the information needed for a conclusion.

For example, a report may describe observations at several timepoints without explaining the basis for a proposed commercial shelf life. Flag that distinction and ask who owns the shelf-life conclusion. Keep the observations, the interpretation and the final decision connected, while preserving their different authors and dates.

FDA says ordinary cosmetics do not have a universally prescribed shelf life or a general federal requirement to print expiration dates. Manufacturers nevertheless remain responsible for safety and determining shelf life. Drug products, including products regulated as both cosmetics and drugs, have different requirements. FDA’s shelf-life explanation.

Microbiological quality: what was found in the sample?

ISO 17516 addresses assessment of cosmetic microbiological quality. Its scope also recognizes that products assessed as microbiologically low risk need not undergo microbiological testing. That is not permission for a brand to declare a product low risk from its marketing description. ISO’s microbiological-limits scope.

For a result used in a lot-related decision, verify the sample and lot identifiers, method reference, specification and reported result. Ask the issuer to resolve an unexplained “pass” rather than inventing the missing specification. A result associated with one identified sample should not silently become a claim about all shipments of the product.

Method identity deserves its own field. FDA’s BAM Chapter 23 page lists a current edition and revision history for its cosmetic methods. Recording only “FDA method” loses information that may be needed to understand what the laboratory actually did. FDA’s cosmetic microbiological methods.

Our recommended evidence summary should reproduce the report’s factual scope in plain language: the named sample was examined using the stated method, with these reported findings. Add the reviewer’s interpretation separately. Avoid converting “not detected under the test conditions” into “free of all microorganisms.”

Preservative efficacy: how was antimicrobial protection evaluated?

ISO 11930:2019 concerns evaluation of a cosmetic product’s antimicrobial protection using preservation-efficacy data, microbiological risk assessment, or both. Its public scope excludes the preservation-efficacy test for products determined to be low microbiological risk under the referenced assessment framework. Confirm the method edition and any amendment used in the actual report. ISO’s preservation-efficacy scope.

A preservative-efficacy report therefore should not be filed as a substitute for every microbial quality result, nor should a favorable microbial result be renamed a challenge test. Ask the laboratory to explain the study type when a supplier’s document title is ambiguous. Preserve the original title and add your classification without editing the source.

FDA identifies multiple routes of contamination, including ingredients, manufacturing, ineffective preservation, packaging, storage and consumer use. This explains why one isolated result cannot stand in for every part of product protection. FDA’s microbiological safety overview.

Check identity before comparing outcomes

Our recommended intake review starts with a match between the report and the commercial product. A report can be technically complete yet difficult to use if its sample name is a laboratory code that no one has connected to the brand’s formula. Obtain that connection from an appropriate source and keep the supporting explanation.

Packaging deserves attention alongside the formula. For EU safety-report preparation, Commission guidance calls for evidence that the composition used in stability testing corresponds to the marketed product. It also discusses stability in the intended packaging. That is an EU reference, not a statement that the same dossier structure is mandated in the United States. European Commission Annex I guidance.

For your operational review, use explicit outcomes: identity confirmed, clarification requested, or applicability awaiting scientific review. A missing package reference is not automatically a failed study; it is a question that needs resolution before you claim coverage of that package.

• Sample: Which product code, formula reference and lot were supplied?
• Package: What container or package configuration was examined?
• Method: Which procedure, edition and deviations are identified?
• Study stage: Is this a protocol, interim result, summary or final report?
• Conclusion: What did the issuer conclude, and what did your reviewer decide?

A hypothetical switch from a jar to a pump

Consider a moisturizer initially developed in a jar and later sold in a pump. The brand receives a stability report for the jar, a microbial result for one pilot lot and an older preservation report. All carry the same commercial product name. This example is hypothetical and does not establish that a particular package change needs a particular study.

The coordinator first records what each file covers. The jar report remains evidence about the tested configuration. The lot result remains tied to its sample. The preservation report is linked to its tested formula and method. None receives a new pump identifier merely because that is the package now being ordered.

The next step is a focused review request describing the packaging change and the available evidence. The scientific reviewer determines what remains relevant, whether a documented justification is supportable, and what further information or work is necessary. A purchasing deadline does not answer those technical questions.

If the reviewer requests additional work, the open item should identify the question to be resolved, the responsible party and the expected output. “Testing pending” is too broad to tell the team whether it is waiting for a protocol, a sample, an interim result or an interpretation.

Read the conclusion together with its boundaries

We recommend reading reports in two passes. First establish provenance and identity. Then read the method, findings, deviations and conclusion with the reviewer. This helps an operational team avoid spending time reconciling numbers from a report that does not yet have a demonstrated connection to its product.

Keep a short limitations note beside each report. It might say that the document is a summary with underlying data requested, that the study is ongoing, or that applicability after a formula change is under review. These notes should describe actual gaps, not imply failures that the issuer did not report.

FDA describes testing as one component of product safety and notes that existing ingredient and similar-formulation data may be useful, while further work may be needed to address gaps. A test purchase alone does not supply the reasoning that connects evidence to the finished product. FDA’s product-testing guidance.

Make the reviewer handoff specific

A useful handoff contains a product identity sheet, the exact reports received, a description of any changes, and a short list of unanswered questions. Ask for a conclusion within a named scope. For example, the question might concern whether existing evidence addresses a package change, rather than whether a whole brand is “compliant.”

Preserve both the report and the reviewer’s response. If a corrected report arrives, retain the previous revision and connect the correction to the issue it resolves. If the reviewer’s conclusion is conditional, record the condition instead of flattening it into an unrestricted approval.

BeautyAssured helps teams collect these materials, track supplier corrections and keep the review decision with the relevant version. The laboratory and qualified reviewer remain responsible for the scientific work. A clear record lets the brand understand what the evidence supports before it is reused in another request.